Karyopharm Tax Provision vs Selling General Administrative Analysis

KPTI Stock

USD 1.15 0.01 0.88%

Karyopharm Therapeutics financial indicator trend analysis is infinitely more than just investigating Karyopharm Therapeutics recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Karyopharm Therapeutics is a good investment. Please check the relationship between Karyopharm Therapeutics Tax Provision and its Selling General Administrative accounts. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Tax Provision vs Selling General Administrative

Tax Provision vs Selling General Administrative Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Karyopharm Therapeutics Tax Provision account and Selling General Administrative. At this time, the significance of the direction appears to have strong relationship.

The correlation between Karyopharm Therapeutics' Tax Provision and Selling General Administrative is 0.66. Overlapping area represents the amount of variation of Tax Provision that can explain the historical movement of Selling General Administrative in the same time period over historical financial statements of Karyopharm Therapeutics, assuming nothing else is changed. The correlation between historical values of Karyopharm Therapeutics' Tax Provision and Selling General Administrative is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Tax Provision of Karyopharm Therapeutics are associated (or correlated) with its Selling General Administrative. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Selling General Administrative has no effect on the direction of Tax Provision i.e., Karyopharm Therapeutics' Tax Provision and Selling General Administrative go up and down completely randomly.

Correlation Coefficient

0.66

Relationship Direction	Positive
Relationship Strength	Significant

View All Relationships

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Selling General Administrative

Most indicators from Karyopharm Therapeutics' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Karyopharm Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.The Karyopharm Therapeutics' current Enterprise Value is estimated to increase to about 1.1 B, while Selling General Administrative is projected to decrease to under 67.5 M.

	2021	2022	2023	2024 (projected)
Gross Profit	206.4M	151.9M	140.6M	147.6M
Total Revenue	209.8M	157.1M	146.0M	153.3M

Gross Profit Total Revenue

Karyopharm Therapeutics fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Shares Outstanding	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Property Plant And Equipment Gross	Total Current Assets	Short Term Debt	Property Plant Equipment	Net Tangible Assets	Common Stock Total Equity	Retained Earnings Total Equity
Total Assets		0.39	0.63	0.09	0.74	0.46	0.16	-0.74	0.39	0.74	0.48	0.44	0.37	0.98	0.74	0.66	0.51	0.88	0.67	0.48	0.99	0.27	0.63	-0.5	0.57	-0.78
Other Current Liab	0.39		0.69	-0.53	0.69	0.74	0.66	-0.72	-0.06	0.14	-0.02	0.17	-0.3	0.33	0.75	0.64	0.83	0.56	0.69	0.56	0.4	-0.23	0.06	-0.6	0.86	-0.65
Total Current Liabilities	0.63	0.69		-0.47	0.63	0.84	0.52	-0.83	0.07	0.46	0.29	0.58	0.14	0.55	0.83	0.75	0.71	0.75	0.82	0.38	0.61	0.04	0.25	-0.76	0.83	-0.81
Total Stockholder Equity	0.09	-0.53	-0.47		-0.05	-0.58	-0.81	0.57	0.53	0.16	0.22	-0.34	-0.23	0.17	-0.48	-0.67	-0.42	-0.29	-0.68	-0.31	0.08	0.72	0.52	0.77	-0.66	0.53
Property Plant And Equipment Net	0.74	0.69	0.63	-0.05		0.6	0.38	-0.67	0.36	0.31	0.36	0.24	-0.13	0.68	0.68	0.55	0.82	0.77	0.58	0.33	0.73	0.26	0.44	-0.39	0.67	-0.68
Current Deferred Revenue	0.46	0.74	0.84	-0.58	0.6		0.58	-0.79	0.12	0.33	0.27	0.47	0.16	0.35	0.82	0.72	0.78	0.64	0.78	0.28	0.43	-0.09	0.05	-0.75	0.86	-0.74
Net Debt	0.16	0.66	0.52	-0.81	0.38	0.58		-0.72	-0.2	-0.28	-0.13	0.06	0.07	0.1	0.69	0.68	0.57	0.49	0.73	0.56	0.18	-0.35	-0.08	-0.65	0.8	-0.67
Retained Earnings	-0.74	-0.72	-0.83	0.57	-0.67	-0.79	-0.72		-0.09	-0.41	-0.27	-0.45	-0.36	-0.67	-0.97	-0.94	-0.72	-0.92	-0.97	-0.66	-0.74	0.18	-0.22	0.88	-0.94	0.99
Accounts Payable	0.39	-0.06	0.07	0.53	0.36	0.12	-0.2	-0.09		0.17	0.33	-0.33	-0.05	0.4	0.25	-0.18	0.08	0.22	-0.1	0.11	0.36	0.76	0.63	0.25	0.03	-0.07
Cash	0.74	0.14	0.46	0.16	0.31	0.33	-0.28	-0.41	0.17		0.31	0.6	0.41	0.75	0.39	0.46	0.27	0.5	0.43	0.13	0.74	0.09	0.31	-0.39	0.27	-0.45
Non Current Assets Total	0.48	-0.02	0.29	0.22	0.36	0.27	-0.13	-0.27	0.33	0.31		0.51	0.44	0.36	0.25	0.21	0.03	0.43	0.18	-0.02	0.36	0.3	0.47	-0.25	0.07	-0.34
Non Currrent Assets Other	0.44	0.17	0.58	-0.34	0.24	0.47	0.06	-0.45	-0.33	0.6	0.51		0.58	0.34	0.31	0.64	0.26	0.48	0.56	-0.08	0.4	-0.27	-0.02	-0.67	0.31	-0.53
Other Assets	0.37	-0.3	0.14	-0.23	-0.13	0.16	0.07	-0.36	-0.05	0.41	0.44	0.58		0.31	0.25	0.5	-0.18	0.41	0.43	0.11	0.33	-0.25	0.03	-0.52	0.11	-0.43
Cash And Short Term Investments	0.98	0.33	0.55	0.17	0.68	0.35	0.1	-0.67	0.4	0.75	0.36	0.34	0.31		0.68	0.59	0.45	0.81	0.6	0.5	0.99	0.31	0.66	-0.39	0.5	-0.7
Common Stock Shares Outstanding	0.74	0.75	0.83	-0.48	0.68	0.82	0.69	-0.97	0.25	0.39	0.25	0.31	0.25	0.68		0.84	0.7	0.87	0.9	0.72	0.73	-0.02	0.36	-0.78	0.94	-0.93
Non Current Liabilities Total	0.66	0.64	0.75	-0.67	0.55	0.72	0.68	-0.94	-0.18	0.46	0.21	0.64	0.5	0.59	0.84		0.65	0.84	0.99	0.55	0.66	-0.41	0.04	-0.95	0.86	-0.95
Other Current Assets	0.51	0.83	0.71	-0.42	0.82	0.78	0.57	-0.72	0.08	0.27	0.03	0.26	-0.18	0.45	0.7	0.65		0.63	0.7	0.21	0.53	-0.07	0.0	-0.57	0.84	-0.69
Other Stockholder Equity	0.88	0.56	0.75	-0.29	0.77	0.64	0.49	-0.92	0.22	0.5	0.43	0.48	0.41	0.81	0.87	0.84	0.63		0.86	0.58	0.87	-0.01	0.37	-0.75	0.79	-0.95
Total Liab	0.67	0.69	0.82	-0.68	0.58	0.78	0.73	-0.97	-0.1	0.43	0.18	0.56	0.43	0.6	0.9	0.99	0.7	0.86		0.59	0.67	-0.34	0.09	-0.94	0.92	-0.97
Property Plant And Equipment Gross	0.48	0.56	0.38	-0.31	0.33	0.28	0.56	-0.66	0.11	0.13	-0.02	-0.08	0.11	0.5	0.72	0.55	0.21	0.58	0.59		0.5	-0.14	0.41	-0.46	0.62	-0.61
Total Current Assets	0.99	0.4	0.61	0.08	0.73	0.43	0.18	-0.74	0.36	0.74	0.36	0.4	0.33	0.99	0.73	0.66	0.53	0.87	0.67	0.5		0.24	0.59	-0.48	0.58	-0.77
Short Term Debt	0.27	-0.23	0.04	0.72	0.26	-0.09	-0.35	0.18	0.76	0.09	0.3	-0.27	-0.25	0.31	-0.02	-0.41	-0.07	-0.01	-0.34	-0.14	0.24		0.76	0.53	-0.23	0.19
Property Plant Equipment	0.63	0.06	0.25	0.52	0.44	0.05	-0.08	-0.22	0.63	0.31	0.47	-0.02	0.03	0.66	0.36	0.04	0.0	0.37	0.09	0.41	0.59	0.76		0.14	0.09	-0.23
Net Tangible Assets	-0.5	-0.6	-0.76	0.77	-0.39	-0.75	-0.65	0.88	0.25	-0.39	-0.25	-0.67	-0.52	-0.39	-0.78	-0.95	-0.57	-0.75	-0.94	-0.46	-0.48	0.53	0.14		-0.83	0.89
Common Stock Total Equity	0.57	0.86	0.83	-0.66	0.67	0.86	0.8	-0.94	0.03	0.27	0.07	0.31	0.11	0.5	0.94	0.86	0.84	0.79	0.92	0.62	0.58	-0.23	0.09	-0.83		-0.89
Retained Earnings Total Equity	-0.78	-0.65	-0.81	0.53	-0.68	-0.74	-0.67	0.99	-0.07	-0.45	-0.34	-0.53	-0.43	-0.7	-0.93	-0.95	-0.69	-0.95	-0.97	-0.61	-0.77	0.19	-0.23	0.89	-0.89

Click cells to compare fundamentals

Karyopharm Therapeutics Account Relationship Matchups

Karyopharm Therapeutics fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	295.0M	313.1M	305.3M	358.2M	240.4M	238.3M
Other Current Liab	41.4M	(6.4M)	678K	60.3M	63.0M	66.2M
Total Current Liabilities	46.4M	297K	73.7M	65.9M	69.5M	73.0M
Total Stockholder Equity	49.8M	50.5M	(79.7M)	(16.7M)	(136.2M)	(129.4M)
Property Plant And Equipment Net	3.0M	2.2M	1.6M	7.4M	4.9M	3.0M
Current Deferred Revenue	9.4M	2.3M	297K	69.1M	79.5M	83.5M
Net Debt	(19.0M)	32.0M	(21.2M)	37.8M	124.1M	130.3M
Retained Earnings	(873.3M)	(1.1B)	(1.2B)	(1.3B)	(1.5B)	(1.4B)
Accounts Payable	985K	4.5M	1.6M	2.8M	3.1M	3.5M
Cash	128.9M	85.9M	190.5M	135.2M	52.9M	101.7M
Non Current Assets Total	21.3M	23.5M	47.2M	31.4M	6.5M	6.2M
Non Currrent Assets Other	16.2M	(2.9M)	44.9M	23.4M	1.3M	1.3M
Other Assets	714K	34.3M	45.6M	633K	1.0	0.95
Cash And Short Term Investments	264.0M	273.5M	228.6M	278.0M	192.1M	201.8M
Common Stock Shares Outstanding	62.0M	72.0M	75.2M	81.9M	114.2M	119.9M
Liabilities And Stockholders Equity	295.0M	313.1M	305.3M	358.2M	240.4M	238.3M
Non Current Liabilities Total	245.2M	262.2M	385.0M	374.8M	307.2M	322.5M
Other Current Assets	1.5M	559K	2.9M	19.8M	11.8M	12.4M
Other Stockholder Equity	923.1M	1.1B	1.1B	1.3B	1.4B	748.9M
Total Liab	245.2M	262.5M	385.0M	374.8M	376.6M	395.5M
Property Plant And Equipment Gross	13.7M	11.6M	1.6M	1.1M	11.4M	12.0M
Total Current Assets	273.7M	289.5M	258.1M	326.8M	233.9M	215.6M
Accumulated Other Comprehensive Income	(37K)	518K	191K	(638K)	(161K)	(169.1K)
Short Term Debt	1.6M	1.9M	2.3M	2.9M	3.3M	5.5M
Property Plant Equipment	3.0M	2.2M	1.6M	1.1M	1.3M	2.2M
Net Tangible Assets	49.8M	50.5M	(79.7M)	(16.7M)	(15.0M)	(14.2M)
Long Term Debt	109.9M	117.9M	169.3M	170.1M	170.9M	179.5M
Retained Earnings Total Equity	(873.3M)	(1.1B)	(1.2B)	(1.3B)	(1.2B)	(1.1B)
Short Term Investments	133.1M	163.3M	38.2M	142.8M	139.2M	115.6M
Capital Surpluse	923.1M	1.1B	1.1B	1.3B	1.5B	824.8M
Other Liab	8.5M	75.8M	144.6M	215.7M	248.0M	260.4M
Net Invested Capital	159.6M	168.5M	169.3M	170.1M	34.7M	33.0M
Net Working Capital	232.2M	216.3M	201.9M	284.3M	164.4M	233.5M
Short Long Term Debt Total	109.9M	117.9M	169.3M	173.0M	177.0M	155.8M

Currently Active Assets on Macroaxis

C	Citigroup
CRM	Salesforce
MSFT	Microsoft
V	Visa Class A
GOOG	Alphabet Inc Class C

When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:

How To Invest In Karyopharm

Details

Is Karyopharm Stock a good investment?

Details

What is Karyopharm Therapeutics' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Karyopharm Therapeutics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate.

For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

You can also try the Theme Ratings module to determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.

	Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
	Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios
	Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges
	Commodity Channel Use Commodity Channel Index to analyze current equity momentum
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
	Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
	Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences

Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.27)

Revenue Per Share

1.224

Quarterly Revenue Growth

(0.14)

Return On Assets

(0.31)

Return On Equity

(8.91)

The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Karyopharm Tax Provision vs Selling General Administrative Analysis

Tax Provision vs Selling General Administrative

Tax Provision vs Selling General Administrative Correlation Analysis

Correlation Coefficient

Tax Provision

Selling General Administrative

Karyopharm Therapeutics fundamental ratios Correlations

Karyopharm Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Karyopharm Therapeutics fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Karyopharm Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 0.99	Total Assets
Retained Earnings Total Equity	+ 0.99	Retained Earnings
Total Current Assets	+ 0.99	Cash And Short Term Investments
Total Liab	+ 0.99	Non Current Liabilities Total
Cash And Short Term Investments	+ 0.98	Total Assets
Common Stock Total Equity	+ 0.94	Common Stock Shares Outstanding

Retained Earnings Total Equity	- 0.97	Total Liab
Total Liab	- 0.97	Retained Earnings
Common Stock Shares Outstanding	- 0.97	Retained Earnings
Retained Earnings Total Equity	- 0.95	Other Stockholder Equity
Retained Earnings Total Equity	- 0.95	Non Current Liabilities Total
Net Tangible Assets	- 0.95	Non Current Liabilities Total